Interleukin-28B polymorphism in hepatitis C and liver transplantation

Liver Transplantation

Volumn 19, Issue 1, 2013, Pages 49-58

  Duarte Rojo, Andres ^a,b   Deneke, Matthew G ^a   Charlton, Michael R ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERLEUKIN 28B; VIRUS RNA;

ACCURACY; ACUTE GRAFT REJECTION; ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; DISEASE COURSE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C; HETEROZYGOTE; HISTOLOGICAL RECURRENCE; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TRANSPLANTATION; METABOLIC DISORDER; MORTALITY; ORGAN DONOR; OSCILLATION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT FAILURE; TREATMENT OUTCOME;

DIABETES MELLITUS; FATTY LIVER; GENOTYPE; GRAFT SURVIVAL; HEPATITIS C; HUMANS; INTERLEUKINS; LIVER TRANSPLANTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84871942070     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23554     Document Type: Review

References (57)

1. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
2. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
3. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
4. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
5. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al.; for Swiss Hepatitis C Cohort Study, for Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study. Gastroenterology 2010; 138: 1338-1345.
6. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.e18.
7. McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, Fischer S, et al. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 2012; 142: 1122-1131.e1.
8. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-1031.
9. Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J, et al.; for DITTO-HCV Study Group. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 2011; 6: e17232.
10. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-827.e1.
11. Lindh M, Lagging M, Färkkilä M, Langeland N, Mørch K, Nilsson S, et al. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 2011; 203: 1748-1752.
12. De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, et al. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012; 55: 336-342.
13. Duarte-Rojo A, Heathcote EJ, Feld JJ,. 'Easy to treat' genotypes were not created equal: can rapid virological response (RVR) level the playing field? J Hepatol 2011; 55: 466-473.
14. Vispo E, Rallon NI, Labarga P, Barreiro P, Benito JM, Soriano V,. Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. J Clin Virol 2012; 55: 58-61.
15. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585.
16. Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, et al. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol 2012; 27: 1467-1472.
17. Coto-Llerena M, Pérez-Del-Pulgar S, Crespo G, Carrión JA, Martínez SM, Sánchez-Tapias JM, et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011; 11: 1051-1057.
18. Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, et al. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 2011; 17: 289-298.
19. Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt KD, Heimbach JK, et al. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation 2012; 94: 197-203.
20. Donato MF, Rigamonti C, Galmozzi E, Aghemo A, Bastiampillai J, Arosio E, et al. Donor/recipient match of IL28B to predict interferon response in recurrent hepatitis C [abstract]. Hepatology 2011; 54 (suppl 1): 450A.
21. Lange CM, Moradpour D, Doehring A, Lehr HA, Müllhaupt B, Bibert S, et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011; 55: 322-327.
22. Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-324.
23. Eurich D, Boas-Knoop S, Bahra M, Neuhaus R, Somasundaram R, Neuhaus P, et al. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 2012; 93: 644-649.
24. Coto-Llerena M, Crespo G, González P, Koutsoudakis G, Miquel R, Navasa M, et al. Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. J Hepatol 2012; 56: 355-358.
25. Donato MF, Galmozzi E, Rigamonti C, Aghemo A,. Post-liver transplantation graft biopsies should not be used to assess the IL28B donor genotype in HCV recipients. J Hepatol 2012; 56: 1422.
26. Chin JL, Nicholas RM, Russell J, Carr M, Connell J, Stewart S, McCormick PA,. Spontaneous clearance of hepatitis C infection after liver transplantation from IL28B rs12979860 CC donors. Eur J Gastroenterol Hepatol 2012; 24: 1110-1112.
27. Balagopal A, Thomas DL, Thio CL,. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139: 1865-1876.
28. Urban T, Charlton MR, Goldstein DB,. Introduction to the genetics and biology of interleukin-28B. Hepatology 2012; 56: 361-366.
29. Megjugorac NJ, Gallagher GE, Gallagher G,. Modulation of human plasmacytoid DC function by IFN-λ1 (IL-29). J Leukoc Biol 2009; 86: 1359-1363.
30. Gallagher G, Megjugorac NJ, Yu RY, Eskdale J, Gallagher GE, Siegel R, Tollar E,. The lambda interferons: guardians of the immune-epithelial interface and the T-helper 2 response. J Interferon Cytokine Res 2010; 30: 603-615.
31. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, Gallagher G,. Human interferon lambda-1 (IFN-λ1/IL-29) modulates the Th1/Th2 response. Genes Immun 2007; 8: 254-261. (Pubitemid 46679436)
32. Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, Cisper N, Weiner DB,. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009; 113: 5868-5877.
33. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al.; for Hokuriku Liver Study Group. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
34. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, et al. Interferon-lambda serum levels in hepatitis C. J Hepatol 2011; 54: 859-865.
35. Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 2011; 55: 980-988.
36. Sadler AJ, Williams BR,. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8: 559-568. (Pubitemid 351913674)
37. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142: 978-988.
38. Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, et al. The complicated relationships of amino acid substitution in HCV core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology 2012; 56: 2134-2141.
39. Veldt BJ, Duarte-Rojo A, Thompson AJ, Watt KD, Heimbach JK, Tillmann HL, et al. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant 2012; 12: 737-744.
40. Bitetto D, Fabris C, Falleti E, Fornasiere E, Avellini C, Cmet S, et al. Recipient interleukin-28B rs12979860 C/T polymorphism and acute cellular rejection after liver transplantation: role of the calcineurin inhibitor used. Transplantation 2012; 93: 1038-1044.
41. Doherty DG, O'Farrelly C,. Innate and adaptive lymphoid cells in the human liver. Immunol Rev 2000; 174: 5-20. (Pubitemid 30201375)
42. Barth H, Rybczynska J, Patient R, Choi Y, Sapp RK, Baumert TF, et al. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology 2011; 54: 1135-1148.
43. Shoukry NH, Pelletier S, Chang KM,. A view to natural killer cells in hepatitis C. Gastroenterology 2011; 141: 1144-1148.
44. Motomura T, Taketomi A, Fukuhara T, Mano Y, Takeishi K, Toshima T, et al. The impact of IL28B genetic variants on recurrent hepatitis C in liver transplantation: significant lessons from a dual graft case. Am J Transplant 2011; 11: 1325-1329.
45. Graziadei IW, Zoller HM, Schloegl A, Nachbaur K, Pfeiffer KP, Mark W, et al. Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation. Liver Transpl 2012; 18: 671-679.
46. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol 2011; 54: 716-722.
47. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009; 9: 1406-1413.
48. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-1896.
49. Taniguchi CM, Emanuelli B, Kahn CR,. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85-96. (Pubitemid 43278292)
50. Pazienza V, Clément S, Pugnale P, Conzelman S, Foti M, Mangia A, Negro F,. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164-1171. (Pubitemid 46775778)
51. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-1508. (Pubitemid 39435150)
52. Brandman D, Pingitore A, Lai JC, Roberts JP, Ferrell L, Bass NM, Terrault NA,. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl 2011; 17: 1380-1386.
53. Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 2011; 55: 1195-1200.
54. Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, Hyogo H, et al. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. J Gastroenterol 2012; 47: 834-844.
55. Charlton M, Ruppert K, Belle SH, Bass N, Schafer D, Wiesner RH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004; 10: 1120-1130. (Pubitemid 39248409)
56. Selzner N, Renner EL, Selzner M, Adeyi O, Kashfi A, Therapondos G, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 2009; 88: 1214-1221.
57. Thompson AJ,. Genetic factors and hepatitis C virus infection. Gastroenterology 2012; 142: 1335-1339.